Germany's health ministry has said that the country's COVID-19 vaccination rollout will not be affected by the trial failure of German biopharmaceutical company CureVac N.V.'s (Nasdaq:CVAC) COVID-19 vaccine, Reuters news agency reported on Thursday.
Results of the Phase 2b/3 study showed that CureVac's COVID-19 vaccine failed to meet its efficacy goal.
CureVac said on Wednesday that the vaccine was only 47% effective in the late-stage trial, missing the study's main goal.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses